HYTN Announces Arrangement Agreement to Facilitate the Spin-Out of a Peptide-Focused Drug Development Business

VANCOUVER, British Columbia, Sept. 02, 2026 (GLOBE NEWSWIRE) — HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC Pink: HYTNF) (“HYTN” or the “Company”), a pharmaceutical manufacturer specializing in products containing psychoactive and psychotropic compounds, announces that it has entered into an arrangement agreement with Peptide Development Labs Inc. (“PDL”) dated September 1, 2026 (the “Arrangement […]